Advertisement

Topics

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

08:38 EDT 12 Jul 2018 | Labiotech.eu

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) ...

The post Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies appeared first on Labiotech.eu.

Original Article: Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

NEXT ARTICLE

More From BioPortfolio on "Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...